Norges Bank’s Prelude Therapeutics PRLD Stock Holding History

Norges Bank’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25,000	Closed	-$311K	–	2217
2021 Q4	$311K	Sell	25,000 -197,400	-89%	-$3.21M	﹤0.01%	2171
2021 Q3	$6.95M	Buy	222,400 +197,400	+790%	+$6.39M	﹤0.01%	1856
2021 Q2	$716K	Hold	25,000	–	–	﹤0.01%	2140
2021 Q1	$1.08M	Buy	25,000 +5,000	+25%	+$332K	﹤0.01%	2043
2020 Q4	$1.43M	Hold	20,000	–	–	﹤0.01%	1989
2020 Q3	$603K	Buy	+20,000	New	+$565K	﹤0.01%	2069

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Norges Bank's PRLD Position: Q1 2022 in Review

Norges Bank sold out of Prelude Therapeutics (PRLD) in Q1 2022, closing a stake of 25,000 shares — an estimated $311K sold.

Norges Bank first reported a position in PRLD in Q3 2020 and held it in 6 quarters. The position peaked at $6.95M in Q3 2021. 68 funds tracked by Wall St. Rank hold PRLD as of Q1 2022.

Norges Bank reported no remaining Prelude Therapeutics position as of Q1 2022 after selling out during the quarter.
Norges Bank sold 25,000 Prelude Therapeutics shares in Q1 2022, an estimated $311K.
Norges Bank first reported a position in Prelude Therapeutics in Q3 2020 and held it in 6 quarters.
Norges Bank's Prelude Therapeutics position peaked at $6.95M in Q3 2021.
68 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2022.

Based on Norges Bank's 13F filing for Q1 2022, filed 9 May 2022.